Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
has an ideal SS for run to silver: 144,578,888 Shares Outstanding and Float is 50 Million. Big Gainz Ahead
https://ibb.co/9Wf1Rqs
Good read thanks FUNMAN. Added more in $2.70’s . NASDAQ, first mover international revenue... basically same price range now for all 3 top extractors. Give me LABS all day, no brainer here!!!
Credit Mariusz, yahoo board:
$UNEQ CEO he has held a position in Stryker Corporation and look who is Stryker Corporation
Stryker Corporation trades at NYSE $209.62 PPS
UNEQ-PRES..Abel Hague's BIO:was Dir.of Bus Dev.@ 12-Bill Stryker-Corp,
He was the Director of business development at the fortune 500 Stryker Corp, he also was the Director of Education and training , he was also in mergers and acquisitions. He has vast experience in international business.
DR Hague is so qualified to expertly manage UNEQ in all levels of business. He is as legit as they come. Hague was the Director of Business. development at Stryker
Director of training & Education STRYKER is a 12 billion dollar Corp
insert-text-here
Abel N J. Haque
President, CEO, Secretary, Treasurer & Director, Uneeqo, Inc.
Presently, Abel N J. Haque holds the position of President, CEO, Secretary, Treasurer & Director at Uneeqo, Inc.n
He previously was Director-Education & Training at Stryker Howmedica Osteonics, Inc., Director-Business Development at Stryker UK Ltd. and Manager-International Product at Huntleigh Healthcare Ltd.
He received a doctorate from The University of Nottingham.
Stryker Corporation is a Fortune 500 medical technologies firm based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment
Stryker Corp In 2017 they had 12 billion in revenues.
MediPharm Labs White Labels Shelter's Wayfarer Vape Cartridges, Delivers First Cannabis 2.0 Shipments
That’s the way I see it !
No problem , there are small controlled fires throughout but major fire is other side , prayers go out to Australia!!!
$LABS is safe
https://ibb.co/2c4RLvh
Nope heard they are getting ready to dispense barrels of CBD to first responders to help with sore muscles and relaxation.
The broker noted that the escrow period for founding shareholders who control 56% of the company will end on January 8, 2019. This means there may be a fresh wave of selling in 2020 – not a great way to start the new year.
https://au-finance-yahoo-com.cdn.ampproject.org/v/s/au.finance.yahoo.com/amphtml/news/why-elixinol-global-share-price-022239016.html?amp_js_v=0.1&usqp=mq331AQCKAE%3D#origin=https%3A%2F%2Fwww.google.com&prerenderSize=1&visibilityState=prerender&paddingTop=32&p2r=0&horizontalScrolling=0&csi=1&aoh=15779283310567&viewerUrl=https%3A%2F%2Fwww.google.com%2Famp%2Fs%2Fau.finance.yahoo.com%2Famphtml%2Fnews%2Fwhy-elixinol-global-share-price-022239016.html&history=1&storage=1&c
You as well
Yep, just all holders should know what happens......gl
Anybody still in this be aware;
The broker noted that the escrow period for founding shareholders who control 56% of the company will end on January 8, 2019. This means there may be a fresh wave of selling in 2020 – not a great way to start the new year.
https://au-finance-yahoo-com.cdn.ampproject.org/v/s/au.finance.yahoo.com/amphtml/news/why-elixinol-global-share-price-022239016.html?amp_js_v=0.1&usqp=mq331AQCKAE%3D#origin=https%3A%2F%2Fwww.google.com&prerenderSize=1&visibilityState=prerender&paddingTop=32&p2r=0&horizontalScrolling=0&csi=1&aoh=15779283310567&viewerUrl=https%3A%2F%2Fwww.google.com%2Famp%2Fs%2Fau.finance.yahoo.com%2Famphtml%2Fnews%2Fwhy-elixinol-global-share-price-022239016.html&history=1&storage=1&cid=1&cap=navigateTo%2Ccid%2CfullReplaceHistory%2Cfragment%2CreplaceUrl%2CiframeScroll
CV Sciences, Inc.
The following documents have been filed with the SEC:
SEC Filing Alert
4: Statement of changes in beneficial ownership of securities
HTML PDF
Last message
Agreed Hmmmmmmm
Yes. See below
https://ibb.co/Wy5D4C2
MAJOR NEWS: MediPharm Labs is pleased to announce it has received @HealthCanada Licence Amendment to Permit Use of tripled footprint within Canadian Facility for Private Label and White Label Production and R&D medipharmlabs.com/news/press-rel…
Some price targets:
https://ibb.co/dGn5CqM
https://ibb.co/Dt2rHs5
Kraken Acquires Remaining 25% of Kraken Power
heavy in mediph and valens, waiting for now on nept.. not sure about their execution right now.
Hmmmm.... are you impressed??
From management
https://ibb.co/5Bz5GJG
From management
https://ibb.co/gTbz6sn
I believe you brother! Been riding the waves
Never mind sold at even, not good vibes with NEPT right now bought more LABS
THE VALENS COMPANY ANNOUNCES TSXV APPROVAL OF NORMAL COURSE ISSUER BID
Kelowna, B.C., December 18, 2019 – Valens GroWorks Corp. (TSXV: VGW) (OTCQX: VGWCF) (the “Company”, “Valens” or “The Valens Company”), a vertically integrated provider of industry leading extraction products and services, including a diverse suite of extraction methodologies, next generation cannabinoid delivery formats and an ISO 17025 accredited analytical lab, announced today that the TSX Venture Exchange (the “TSXV”) has approved its notice of intention to make a normal course issuer bid for its common shares (“Shares”) as appropriate opportunities arise from time to time. Valens’ normal course issuer bid will be made in accordance with the policies of the TSXV. Valens may purchase its Shares during the period from December 19, 2019 to December 18, 2020.
Pursuant to the notice and subject to the market price of its Shares and other considerations, Valens may acquire over the next 12 months up to 6,275,204 Shares, representing 5% of the outstanding Shares, for cancellation. There are 125,504,096 Shares outstanding as of December 12, 2019. Any purchases will be made at market prices through the facilities of the TSXV. Valens believes that the purchase of its outstanding Shares may be an appropriate use of its resources over the next 12 months, based upon the market price of its Shares during such period. AltaCorp Capital Inc. has been appointed by Valens as broker to conduct the normal course issuer bid.
About The Valens Company
The Valens Company is a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products. The Company is focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and white label product development and manufacturing. Valens is the largest third-party extraction company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. The Valens Company currently offers a wide range of product formats, including tinctures, two-piece caps, soft gels, oral sprays and vape pens as well as beverages, concentrates, topicals, edibles, injectables, natural health products and has a strong pipeline of next generation products in development for future release. Finally, the Company’s wholly-owned subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science. Effective at the start of trading on December 19, 2019, The Valens Company will trade on the TSXV under the ticker VLNS. The Company expects to formally change its name in due course (with its ticker changing on the OTCQX once final regulatory approvals are received). For more information, please visit http://thevalenscompany.com. The Company's investor deck can be found specifically at http://thevalenscompany.com/investors/.
For further information, please contact:
Jeff Fallows
The Valens Company
Telephone: +1.778.755.0052
KCSA Strategic Communications
Phil Carlson / Elizabeth Barker
VGW@kcsa.com
212.896.1233 / 212.896.1203
Media
KCSA Strategic Communications
Anne Donohoe
adonohoe@kcsa.com
212.896.1265
Notice regarding Forward Looking Statements
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”, "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", “positioned” and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
The TSXV or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.
Copyright © 2019 Valens Groworks, All rights reserved.
You are receiving this list because you signed up via the Valens Groworks website.
Our mailing address is:
Valens Groworks
230 Carion Rd
Kelowna, Bc V4V 2K5
Canada
Add us to your address book
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.
Facebook
Twitter
Link
Website
December investor presentation.....
https://thevalenscompany.com/wp-content/uploads/2019/12/InvestorDeck_Dec2019-VGW.pdf
Hey friends started a position today at $2.63 , was surprised that it filled and not sure if I’m happy about it lol, longs here can you update me as to any catalysts here and what you think of Neptune as a long hold or perhaps a flip. It’s been a quiet stock compared to other extractors . Appreciate any honest insight!!!
Zzzzz...me too lol
Rebrand provides strategic clarity on Company's position as a global leader in the end-to-end development and manufacturing of cannabinoid-based products
https://www.prnewswire.com/news-releases/valens-groworks-corp-rebrands-to-the-valens-company-demonstrating-leadership-in-both-extraction-and-commercializing-innovative-cannabinoid-based-products-300976475.html
Had to too